Drug details

Qelbree (viloxazine extended-release capsules)

type of ADHD Agents, Norepinephrine Reuptake Inhibitors, Selective

Qelbree (viloxazine extended-release capsules) is a selective norepinephrine reuptake inhibitor (SNRI) used to treat Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

This drug may have the following side effects:

• nausea,
• vomiting,
• fever
• upper respiratory tract infection,
• headache,
• fatigue,
• drowsiness,
• insomnia,
• irritability,
• abdominal pain, and
• decreased appetite,

The following drugs are related to Qelbree, either as a replacement or used together:

• Adderall (amphetamine, dextroamphetamine mixed salts)
• Adderall XR (amphetamine, dextroamphetamine mixed salts)
• Strattera (atomoxetine hcl)
• Kapvay (clonidine hydrochloride extended-release tablets)
• Concerta (methylphenidate extended-release tablets)
• Daytrana (methylphenidate transdermal)
• Dexedrine Spansule (dextroamphetamine capsules)
• Focalin XR (dexmethylphenidate hydrochloride)
• Focalin (dexmethylphenidate hydrochloride)
• Xelstrym (dextroamphetamine)
• ProCentra (dextroamphetamine sulfate oral solution)
• Intuniv (guanfacine)
• Vyvanse (lisdexamfetamine dimesylate)
• Metadate CD (methylphenidate hydrochloride extended-release capsules)
• Metadate ER (methylphenidate hydrochloride extended release tablet)
• Ritalin (methylphenidate hcl)
• Quillivant XR (methylphenidate hydrochloride extended release oral suspension, cii)
• Ritalin LA (methylphenidate hydrochloride extended-release capsules)